Effect of sorafenib on serum hepatoma marker in patients with advanced hepatocellular carcinoma / 中国生化药物杂志
Xuhui HE; Meng CHEN; Jinxiu PENG; Jianxin LI; Xueqiang ZHANG; Xuhui HE; Meng CHEN; Jinxiu PENG; Jianxin LI; Xueqiang ZHANG.
Chinese Journal of Biochemical Pharmaceutics
; (6): 91-94, 2015.
Artículo
en Zh
| WPRIM | ID: wpr-463369
Objective To investigate effect of sorafenib on serum hepatoma marker in patients with advanced hepatocellular carcinoma. Methods 101 patients with advanced hepatocellular carcinoma were selected, and divided into two groups.50 cases in control group were treated with routine clinical treatment, and 51 cases in experimental group were treated with sorafenib on the basis of control group.The survival time, adverse reactions, VEGF, CTGF, HIF-1 and OPN levels were compared after the treatment.Results The survival time of experimental group was higher than control group (P<0.05).Compared with control group, the serum levels of VEGF、CTGF,HIF-1, OPN,AFP, CEA, and CA199 in experiment group were lower (P<0.05,P <0.01).There were no significant differences of total adverse reactions between experimental group and control group. Conclusion Sorafenib can effectively prolong survival time of patients with advanced hepatocellular carcinoma, reduce serum VEGF, CTGF, HIF-1 alpha and OPN levels.
Biblioteca responsable:
WPRO
Texto completo
Documentos relacionados